An encouraging outcome of the DUET studies is that etravirine is effective against HIV mutations resistant to existing NNRTIs, efavirenz and nevirapine.
Salvage therapy
ASHM 2006: Strategies for coping with multiple drug resistance
From the December 2006 issue of Positive Living
Finding effective treatment options for people who have taken many treatments and have multiple resistance mutations continues to be a significant challenge for HIV clinicians, and their patients.
Nes and Treatments Briefs
From the December 2006 issue of Positive Living
HIV-related news in brief from the December 2006 edition of Positive Living. Time to deliver
From the October 2006 issue of Positive Living
The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports.
The T-20 conundrum
From the April 2006 issue of Positive Living
What is the place of T-20 in the spectrum of HIV treatment, and when is the best time to start treatment on T-20? These were among the questions considered at a meeting in Sydney on Saturday 8 April. 
Getting spine: the nucleoside backbone
From the December 2005 issue of Positive Living
Nucleoside analogues are the backbone of successful anti-HIV treatments. This article examines some of the issues involved in selecting the best nucleoside backbone.
What’s your problem?
From the August 2005 issue of Positive Living
Our resident medical expert, Dr Nick Medland, answers readers' letters.
Rescue me
From the April 2005 issue of Positive Living
What are the options when you’re running out of options?
Leadership needed
From the October 2004 issue of Positive Living
Australia must re-energise its response to HIV/AIDS, not just rest on its laurels as an early leader, the 2004 ASHM Conference was told in October.
'The greatest health crisis in human history'
From the August 2003 issue of Positive Living
The major international AIDS conference for 2003 has ended with encouraging signs of growing international commitment to fight AIDS in the developing world, and with several promising medical developments.